Can a new biologic boost the immune System's fight against advanced tumors?

NCT ID NCT05382325

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental biologic called MK-1484, given alone or with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced or metastatic solid tumors. The main goal is to assess the safety and tolerability of the treatment and to find a recommended dose for future studies. Participants will receive the drug via injection or infusion, and researchers will monitor for side effects and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-1484 (an experimental biologic) given alone or with pembrolizumab (Keytruda)
What this could lead to: If safe and effective, this combination could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it is too soon to know if the treatment will work. There are risks of side effects, and the drug may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

Erasmus Medisch Centrum-Medical Oncology ( Site 0036)

Rotterdam, South Holland, 3015 GD, Netherlands
NEXT Oncology ( Site 0001)

San Antonio, Texas, 78229, United States
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0035)

Amsterdam, North Holland, 1066CX, Netherlands
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011)

Toronto, Ontario, M5G 2M9, Canada
Rambam Health Care Campus-Oncology ( Site 0021)

Haifa, 3109601, Israel
Sanford Cancer Center ( Site 0005)

Sioux Falls, South Dakota, 57104, United States
Sheba Medical Center-ONCOLOGY ( Site 0020)

Ramat Gan, 5265601, Israel
Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037)

Utrecht, 3584 CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.